STAT+: New federal rule will require prescription drug middlemen to share secret payments data — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Trump administration finalized a regulation Thursday requiring pharmacy benefit managers to disclose fees and compensation to the employers that hire them.
- July 1, 2027 is the start date for disclosures covering drug rebates, spread pricing, and financial relationships with brokers and consultants that could create conflicts of interest.
- Federal officials estimate the rule will cover more than 70 PBMs and 130,000 employers.
- The estimated savings exceed $800 million annually through lower drug costs, according to federal officials.
- Highly protected data on PBM compensation will be unlocked for employer clients by the required disclosures.
Why it matters: The 130,000 employers covered by the rule will receive the disclosures, including rebates, spread pricing and financial ties that could create conflicts of interest; federal officials estimate the change will produce more than $800 million a year in savings through lower drug costs.
Ask SkimNews
